Larsen & Toubro reported a 14% profit growth for the June quarter, while Rail Vikas Nigam secured a ₹359 crore EPC contract for railway doubling works. Investors are assessing these results alongside DCM Shriram’s profit surge and the sharp decline in Phoenix Mills shares.
Larsen & Toubro (L&T) shares rose nearly 4% in today's trade after the company delivered its June quarter results. The engineering giant reported a net profit of ₹4,123 crore, marking a 14% increase compared to the same period last year. Revenue for the quarter stood at ₹67,942 crore, representing a 7% growth. The performance highlights the company's ongoing execution of its large infrastructure order book, which remains a key metric for investors tracking its long-term project delivery capabilities.
Rail Vikas Nigam (RVNL) also saw its stock price climb 3% following the announcement of a new contract. The company received a Letter of Acceptance from the East Central Railway for an Engineering, Procurement, and Construction (EPC) contract. The project, valued at approximately ₹358.97 crore, involves doubling works on a railway section. Investors typically monitor these order wins as they provide visibility on future revenue streams, though the ultimate benefit to margins will depend on the cost of raw materials and the speed of project execution.
DCM Shriram shares saw a notable 4% gain after the company reported a sharp jump in net profit, which grew more than six times to ₹692.8 crore for the June quarter. This profit figure was bolstered by revenue of ₹3,784.7 crore, a 9.5% increase year-on-year, and includes exceptional gains of ₹79.42 crore. Meanwhile, the market reacted differently to other results. Phoenix Mills shares dropped 5%, despite reporting a 23.3% rise in profit to ₹296.9 crore and revenue growth of 12.8% to ₹1,074.9 crore. The price movement suggests that investors may have had higher expectations for the company's performance or were concerned about specific operational metrics.
In other market updates, Birlasoft shares gained 1.2% following a 51.3% increase in its quarterly profit to ₹161 crore, with revenue growing 7.4% to ₹1,379.4 crore. Biocon shares saw a marginal decline. While the company's Canadian subsidiary received regulatory approval for an ustekinumab autoinjector from Health Canada, this positive news did not immediately support the stock price. Investors will likely continue to evaluate these quarterly results to see if the growth trends in profit and revenue are sustainable in the coming quarters, particularly as companies navigate fluctuating input costs and shifting demand in their respective sectors.